Is the System Rigged Against Biosimilars?
If you think prescription drug costs are high now, imagine what costs would be without generic drugs. Roughly 25% of total prescription drug sales in 2016 were generics. But it's a different story altogether for biologics -- drugs made from living organisms or components of living organisms. Until 2010, biosimilars to biologics weren't even legally allowed in the U.S.
Seven years later, biosimilars still haven't made a huge dent in helping control soaring drug costs in therapeutic categories like autoimmune diseases, where biologics dominate. Could it be that the system is rigged against biosimilars?
Image source: Getty Images.
Source: Fool.com
Pfizer Inc. Stock
€22.48
0.650%
We see a rather positive sentiment for Pfizer Inc. with 15 Buy predictions and 2 Sell predictions.
As a result the target price of 29 € shows a positive potential of 29.0% compared to the current price of 22.48 € for Pfizer Inc..
